- Home
- BMO vs PFE Comparison
BMO vs PFE Comparison
Compare BMO & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | PFE |
|---|---|---|
| Founded | 1817 | 1849 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.2B | 147.6B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BMO | PFE |
|---|---|---|
| Price | $173.72 | $28.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $163.00 | $29.29 |
| AVG Volume (30 Days) | 655.4K | ★ 32.8M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | 3.25% | ★ 6.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | $19.43 | N/A |
| Revenue Next Year | $4.27 | N/A |
| P/E Ratio | ★ $17.46 | $65.06 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $118.13 | $23.59 |
| 52 Week High | $187.22 | $28.75 |
Technical Indicators
Market Signals| Indicator | BMO | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 69.03 |
| Support Level | $147.71 | $24.90 |
| Resistance Level | $185.72 | $28.75 |
| Average True Range (ATR) | 3.11 | 0.52 |
| MACD | -1.41 | 0.13 |
| Stochastic Oscillator | 14.40 | 81.71 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial services provider based in North America with over CAD 1.47 trillion in assets by the end of fiscal 2025. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. About 60% of BMO's earnings are generated in Canada and 40% in the US.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.